Key facts
- It has raised $5.5M across 1 recorded rounds; the latest was Early Stage VC ($5.5M) in Oct 2022.
- Notable investors include Johnson & Johnson Innovation - JLABS, Cancer Prevention and Research Institute of Texas.
- Bectas Therapeutics has filed 2 Form Ds with the SEC since 2024, most recently Oct 2025 ($5.5M sold to 13 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Bectas Therapeutics
Funding rounds
1 roundsAbout Bectas Therapeutics
Developer of a monoclonal antibody therapy designed to realize the full potential of the immune system. The company combines monoclonal antibodies that exhibit pre-clinical activity with precision information, enabling the healthcare industry to serve patients across multiple cancer indications.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2022
- Employees
- 3
- Website
- bectastx.com/
- Ownership
- Privately Held (backing)
Bectas Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bectas Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bectas Therapeutics in its N-PORT filings yet. We sweep new filings monthly.